Table 1 Overview of trials, key end points and time to treatment for primary angioplasty (A) and thrombolysis (T).
| Study | 1 Month (4–6 weeks) | 6 Months | Time (min) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No | Death | NF Reinf | NF Stroke | No | Death | NF Reinf | NF Stroke | Mean | Mean | |||||||||
| (A) | (T) | No (A)/(T) | OR (95% CrI) | No (A)/(T) | OR (95% CrI) | No (A)/(T) | OR (95% CrI) | (A) | (T) | No (A)/(T) | OR (95% CrI) | No (A)/(T) | OR (95% CrI) | No (A)/(T) | OR (95% CrI) | (A) | (T) | |
| Zijlstra et al 199323‡ | 70 | 72 | 0/4 | 0.1 (0 to 7.7) | 0/9 | 0.1 (0.0 to 4.8) | 0/2 | 0.2 (0.0 to 12.4) | – | – | – | – | – | – | – | – | 61 | 30 |
| Ribeiro et al 199324‡ | 50 | 50 | 3/1 | 3.1 (0.2 to 16) | 4/5 | 0.7 (0.2 to 3.5) | – | – | – | – | – | – | – | – | – | – | 238 | 179 |
| de Boer et al 199419‡ | 152 | 149 | 3/11 | 0.3 (0.2 to 2) | 2/15 | 0.1 (0.0 to 1.7) | 1/2 | 0.4 (0.0 to 8.1) | – | – | – | – | – | – | – | – | 195 | 176 |
| Berrocal et al 200320‡ | 54 | 58 | 5/6 | 0.9 (0.3 to 3.3) | 1/2 | 0.5 (0.0 to 8.6) | – | – | – | – | – | – | – | – | – | – | 82 | 15 |
| Zijlstra et al 199725‡ | 45 | 50 | 1/0 | 2.3 (0 to 43) | 0/8 | 0.0 (0.0 to 5.2) | 1/2 | 0.5 (0.0 to 8.7) | 45 | 50 | 1/0 | 2.2 (0.0 to 43.4) | 0/8 | 0.0 (0.0 to 5.2) | 1/2 | 0.5 (0.0 to 8.7) | 68 | 29 |
| Widimsky et al 200026‡ | 101 | 99 | 7/14 | 0.5 (0.3 to 1.8) | 1/10 | 0.0 (0.0 to 2.7) | 0/0 | 1 (0.0 to 50.4) | – | – | – | – | – | – | – | – | 96 | 90 |
| de Boer et al 200227‡ | 46 | 41 | 3/8 | 0.3 (0.1 to 2.4) | 1/6 | 0.1 (0.0 to 3.5) | 1/2 | 0.4 (0.0 to 7.9) | – | – | – | – | – | – | – | – | 59 | 31 |
| Widimsky et al 200321†‡ | 429 | 421 | 29/42 | 0.7 (0.5 to 1.4) | 6/13 | 0.4 (0.2 to 1.8) | 1/9 | 0.1 (0.0 to 3.0) | – | – | – | – | – | – | – | – | 97 | 12 |
| DeWood et al 199028 | 46 | 44 | 3/2 | 1.5 (0.2 to 7.4) | – | – | – | – | – | – | – | – | – | – | – | – | 126 | 84 |
| Grines et al 199329 | 195 | 200 | 5/13 | 0.4 (0.2 to 1.9) | 5/13 | 0.3 (0.2 to 1.8) | 0/3 | 0.1 (0.0 to 9.2) | 188 | 190 | 7/15 | 0.4 (0.2 to 1.7) | – | – | – | – | 60 | 32 |
| Gibbons et al 199330 | 47 | 56 | 2/2 | 1.2 (0.1 to 8) | – | – | – | – | 47 | 56 | 3/2 | 1.8 (0.2 to 8.1) | 0/2 | 0.2 (0.0 to 13.2) | – | – | 277 | 232 |
| Ribichini et al 199831 | 55 | 55 | 1/3 | 0.3 (0.1 to 6.1) | 1/2 | 0.4 (0.0 to 8.3) | 0/0 | 1 (0.0 to 51.31) | 55 | 55 | 1/4 | 0.2 (0.0 to 4.9) | 2/2 | 1 (0.1 to 7.3) | – | – | 53.2 | 36.5 |
| Garcia et al 199932 | 109 | 111 | 3/12 | 0.2 (0.1 to 1.9) | 4/6 | 0.6 (0.2 to 3.0) | 0/2 | 0.2 (0.0 to 12.3) | 99 | 91 | 5/13 | 0.3 (0.2 to 1.7) | 6/8 | 0.6 (0.2 to 2.5) | – | – | 197 | 150 |
| GUSTO IIb 199733 | 565 | 573 | 32/40 | 0.8 (0.6 to 1.5) | 25/37 | 0.6 (0.4 to 1.4) | 1/5 | 0.2 (0.0 to 4.2) | 565 | 573 | – | – | – | – | – | – | 228 | 180 |
| Le May et al 200134 | 62 | 61 | 3/2 | 1.5 (0.2 to 7.4) | 3/5 | 0.5 (0.1 to 3.4) | 1/1 | 1 (0.0 to 16.2) | 62 | 61 | 3/2 | 1.5 (0.1 to 7.3) | 4/10 | 0.3 (0.1 to 2.1) | 1/3 | 0.3 (0.0 to 6.0) | 77 | 15 |
| Bonnefoy et al 200235 | 421 | 419 | 20/16 | 1.3 (0.6 to 2.2) | 7/15 | 0.4 (0.2 to 1.7) | 0/4 | 0.1 (0.0 to 7.6) | – | – | – | – | – | – | – | – | 190 | 130 |
| Schomig et al 200036 | 71 | 69 | 3/5 | 0.6 (0.2 to 3.4) | 2/4 | 0.4 (0.1 to 4.0) | – | – | 71 | 69 | 3/9 | 0.2 (0.1 to 2.2) | – | – | – | – | 65 | 30 |
| Vermeer et al 199937† | 75 | 75 | 5/5 | 1 (0.3 to 036) | 1/7 | 0.1 (0.0 to 3.4) | 2/1 | 2 (0.1 to 15.3) | – | – | – | – | – | – | – | – | 85 | 10 |
| Kastrati et al 200238 | 81 | 81 | 2/5 | 0.4 (0.1 to 3.5) | 0/4 | 0.1 (0.0 to 7.6) | 1/1 | 1 (0.0 to 16.2) | 70 | 71 | 5/7 | 0.7 (0.2 to 2.8) | – | – | – | – | 75 | 35 |
| Aversano et al 200239 | 225 | 226 | 12/16 | 0.7 (0.4 to 1.9) | 11/20 | 0.5 (0.3 to 1.6) | 3/8 | 0.3 (0.1 to 2.4) | 225 | 226 | 14/16 | 0.8 ( 0.4 to 1.9) | 12/24 | 0.4 (0.3 to 1.4) | 5/9 | 0.5 (0.2 to 2.3) | 101.5 | 46 |
| Grines et al 200240 | 71 | 66 | 6/8 | 0.7 (0.3 to 2.6) | 1/0 | 1.8 (0 to 39.7) | 0/3 | 0.1 (0.0 to 8.9) | – | – | – | – | – | – | – | – | 174 | 63 |
| Andersen et al 2003: Referral22* | 567 | 562 | 37/48 | 0.7 (0.6 to 1.4) | 11/35 | 0.2 (0.2 to 1.1) | 9/11 | 0.8 (0.3 to 2.2) | – | – | – | – | – | – | – | – | 90 | 20 |
| Andersen et al 2003: Invasive22* | 223 | 220 | 15/13 | 1.1 (0.5 to 2.3) | 2/14 | 0.1 (0.0 to 1.8) | 0/5 | 0.0 (0.0 to 6.6) | – | – | – | – | – | – | – | – | 63 | 20 |
Reinf, reinfarction; CrI, credibility interval.
*This trial consisted of two subtrials, labelled “Referral” and “Invasive”, and these are analysed as if they are two separate studies.
†Includes a third group of patients who received thrombolytic treatment followed by transfer to angioplasty; these third comparators were excluded from the present analysis.
‡Trial used streptokinase as part the thrombolytic arm, all other trials used tissue plasminogen activator.